Natera

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

OncoCyte Corp0KCC · BiotechUnited States

70% matchPublic

Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle. Another significant offering, DetermaIO, is a gene expression assay designed to evaluate the tumor microenvironment, thereby helping to predict a patient's potential response to immunotherapies. In the critical field of organ transplantation, Insight Molecular Diagnostics provides several vital monitoring products. Both VitaGraft Kidney and VitaGraft Liver are blood-based tests that precisely measure the concentration of donor-derived cell-free DNA (dd-cfDNA) to assess the status of kidney and liver transplants, respectively. Additionally, GraftAssure represents a sophisticated dd-cfDNA test that leverages droplet digital PCR (ddPCR) technology to quantify dd-cfDNA levels by examining 48 predefined single nucleotide polymorphisms (SNPs). Beyond its product offerings, the company delivers various specialized services, including biomarker discovery, comprehensive assay design and development, support for clinical trials, and a range of general biomarker testing. Furthermore, Insight Molecular Diagnostics maintains a strategic partnership with Bio-Rad Laboratories, Inc. This collaboration focuses on the advancement and commercialization of kitted transplant products for both research use only and in vitro diagnostics applications, utilizing Bio-Rad's proprietary ddPCR instruments and reagents. Founded in 2009, the company's headquarters are situated in Nashville, Tennessee.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

BillionToOneBLLN · BiotechMenlo Park, United States

69% matchPublic

BillionToOne is a molecular diagnostics company that develops single-molecule counting technology for prenatal screening and oncology. The company provides non-invasive prenatal tests (NIPT) to assess fetal risk from maternal blood samples, alongside pan-cancer liquid biopsy tests for therapy selection and treatment monitoring.

VeracyteVCYT · BiotechSouth San Francisco, United States

69% matchPublicAI 37/100 ▼Green 0/100 ▼

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

NeoGenomics, Inc.NEO · BiotechFort Myers, United States

68% matchPublic

NeoGenomics, Inc. is a specialized clinical laboratory company headquartered in Fort Myers, Florida. It operates a network of CAP-accredited and CLIA-certified laboratories to provide comprehensive oncology testing and sample processing services.